Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Tenalisib|DRUG: Tenalisib
Sponsor: Rhizen Pharmaceuticals SA